摘要
非酒精性脂肪性肝病(NAFLD)是一种发病机制复杂多样的慢性肝病,临床上尚无有效治疗手段和特效药用于其治疗。近年来,其发病率呈上升趋势,治疗相关患病人群成为国内外医学研究者的殷切期盼。腺苷酸活化蛋白激酶(AMPK)的作用为调节细胞能量稳态与线粒体稳态,被激活时对于脂质代谢紊乱和线粒体稳态失调贯穿始终的NAFLD疾病进程有良好的干预作用。激活AMPK对于NAFLD能抑制肝脏新生脂肪生成、促进肝脏脂肪酸氧化、增强脂肪组织线粒体功能,而作为代谢性疾病的关键靶点,AMPK还有改善细胞凋亡、肝纤维化、自噬和炎症等作用。中药擅长从多靶点、多途径治疗疾病,在临床上也常用于慢性肝病的治疗。针对NAFLD的大量体内外实验研究表明,中药单体通过AMPK信号通路对治疗NAFLD有着良好的前景,包括苷类、酚类、生物碱类、黄酮类、醌类、萜类、木脂素类在内的多种类型中药单体是AMPK的天然激活剂,该文通过综述中药单体调控AMPK通路防治NAFLD的研究进展,为中药治疗NAFLD提供更广阔的视野。
Non-alcoholic fatty liver disease(NAFLD)is a chronic liver disease with complex and diverse pathogenesis,and there is no effective treatment or specific drugs for its clinical treatment.In recent years,its incidence has been on the rise,and it has become the earnest expectation of medical researchers in China and abroad that related patients could be treated.AMP-activated protein kinase(AMPK)functions to regulate cellular energy homeostasis and mitochondrial homeostasis.When activated,it has a good intervention effect on NAFLD progression with lipid metabolism disorders and mitochondrial homeostasis disorders.For NAFLD,the activation of AMPK can inhibit the production of new lipogenesis in the liver,promote the oxidation of fatty acids in the liver,and enhance the mitochondrial function of adipose tissues.As a key target of metabolic diseases,AMPK can also improve apoptosis,liver fibrosis,autophagy,and inflammation.Traditional Chinese medicine(TCM)is good at treating diseases from multiple targets and multiple pathways and is also commonly used in the treatment of chronic liver disease in clinical practice.A large number of in vitro and in vivo experimental studies on NAFLD have shown that TCM monomers have good prospects for the treatment of NAFLD through the AMPK signaling pathway,including glycosides,phenols,alkaloids,flavonoids,quinones,terpenoids,and lignans,which are natural activators of AMPK.This study reviewed the research progress on TCM monomers in regulating the AMPK pathway to prevent and treat NAFLD,providing a broader perspective for TCM treatment of NAFLD.
作者
黄劲
苏连杰
冯杰
樊锐锋
HUANG Jin;SU Lianjie;FENG Jie;FAN Ruifeng(School of Pharmacy,Heilongjiang University of Chinese Medicine,Harbin 150040,China;Harbin Gloria Pharmaceuticals Co.Ltd.,Harbin 150040,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2023年第4期272-282,共11页
Chinese Journal of Experimental Traditional Medical Formulae
基金
黑龙江省自然科学基金项目(LH2021H095)。
